| Literature DB >> 31763952 |
Ilaria Testi1, Rupesh Agrawal2,3,4, Sarakshi Mahajan5, Aniruddha Agarwal6, Dinesh Visva Gunasekeran2,3, Dhananjay Raje7, Kanika Aggarwal6, Somasheila I Murthy8, Mark Westcott1, Soon Phaik Chee4,9, Peter McCluskey10, Su Ling Ho2, Stephen Teoh2, Luca Cimino11, Jyotirmay Biswas12, Shishir Narain13, Manisha Agarwal14, Padmamalini Mahendradas15, Moncef Khairallah16, Nicholas Jones17, Ilknur Tugal-Tutkun18, Kalpana Babu19, Soumayava Basu20, Ester Carreño21, Richard Lee22, Hassan Al-Dhibi23, Bahram Bodaghi24, Alessandro Invernizzi25, Debra A Goldstein26, Carl P Herbort27, Talin Barisani-Asenbauer28, Julio J González-López29, Sofia Androudi30, Reema Bansal6, Bruttendu Moharana6, Simona Degli Esposti3, Anastasia Tasiopoulou1, Sengal Nadarajah1, Mamta Agarwal12, Sharanya Abraham12, Ruchi Vala15, Ramandeep Singh6, Aman Sharma31, Kusum Sharma32, Manfred Zierhut33, Andres Rousselot34, Robert Grant35, Onn Min Kon36, Emmett T Cunningham37, John Kempen38,39, Quan Dong Nguyen5, Carlos Pavesio1, Vishali Gupta6.
Abstract
Background: Tuberculosis (TB) is a major infection that can affect the eye as first and sole presentation without features of systemic disease. Controversy exists regarding diagnosis and management of tubercular uveitis (TBU), further compounded by regional variations in disease expression. Purpose: Collaborative Ocular Tuberculosis Study (COTS)-1 aims to address knowledge deficits through collaboration amongst uveitis specialists across the globe by sharing the data of patients with TBU presented at participating centers from January 2004 to December 2014.Entities:
Keywords: Anti-tubercular therapy; Collaborative Ocular Tuberculosis Study (COTS); choroiditis; global experts; tubercular uveitis; tuberculosis
Year: 2019 PMID: 31763952 DOI: 10.1080/09273948.2019.1646774
Source DB: PubMed Journal: Ocul Immunol Inflamm ISSN: 0927-3948 Impact factor: 3.728